Perrigo (NYSE:PRGO) Shares Gap Down – Time to Sell?

Perrigo Company plc (NYSE:PRGO)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $11.61, but opened at $11.00. Perrigo shares last traded at $11.3270, with a volume of 758,489 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Weiss Ratings cut Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. Finally, Canaccord Genuity Group cut their price target on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Perrigo currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Price Performance

The company has a 50 day simple moving average of $11.18 and a 200-day simple moving average of $12.47. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -0.85, a PEG ratio of 1.33 and a beta of 0.51. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm had revenue of $841.80 million for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Perrigo’s revenue for the quarter was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, research analysts anticipate that Perrigo Company plc will post 2.11 EPS for the current fiscal year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be paid a dividend of $0.29 per share. The ex-dividend date is Friday, May 29th. This represents a $1.16 annualized dividend and a yield of 10.4%. Perrigo’s dividend payout ratio is presently -8.85%.

Hedge Funds Weigh In On Perrigo

Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC grew its holdings in shares of Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Perrigo during the fourth quarter valued at approximately $28,000. Finally, CWM LLC grew its holdings in shares of Perrigo by 230.0% during the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after purchasing an additional 1,527 shares during the last quarter. 95.91% of the stock is owned by institutional investors.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.